Drug intelligence / Profile preview

VAP-X

Development stage: Preclinical
Lead developer: Infex Therapeutics
Modality: Small Molecules

Overview

VAP-X is a preclinical anti-virulence drug candidate being developed by Infex Therapeutics in collaboration with Microbiotix for the treatment of acute *Pseudomonas aeruginosa* infections, including ventilator-associated pneumonia (VAP). Unlike traditional antibiotics that kill or inhibit the growth of bacteria, VAP-X is designed to target and inhibit the virulence mechanisms of the pathogen. By disarming the bacteria's ability to cause tissue damage and evade the host immune response, the drug aims to reduce the severity of infection without exerting the direct bactericidal pressure that often leads to the development of multi-drug resistance. The program has received support from CARB-X and is currently in the lead optimization phase.

Other names: VAP-X

Targets

T3SS (Pseudomonas aeruginosa type III secretion system)

Beyond the preview

Go deeper on VAP-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAP-X.

Explore the full profile